Ryman Healthcare Limited (NZE:RYM)
2.050
-0.010 (-0.49%)
Aug 7, 2026, 4:59 PM NZST
Ryman Healthcare Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Ryman Healthcare stock has a consensus rating of "Buy" and an average price target of $2.94. The average 1-year stock price forecast is 43.41% higher than the current stock price, while the lowest is $2.56 (+24.88%) and the highest is $3.50 (+70.73%).
Price Target: $2.94 (+43.41%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ryman Healthcare stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 3 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Macquarie No rating | Macquarie | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 16, 2026 |
| Jarden | Jarden | Hold Maintains $3.04 | Hold | Maintains | $3.04 | +48.46% | Jul 15, 2026 |
| UBS | UBS | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 17, 2026 |
Financial Forecast
Revenue This Year
946.67M
from 854.47M
Increased by 10.79%
Revenue Next Year
1.02B
from 946.67M
Increased by 7.53%
EPS This Year
0.12
from -0.17
EPS Next Year
0.18
from 0.12
Increased by 54.81%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is NZD.